Literature DB >> 8013701

The effect of surgery on the AC/A ratio.

E Lucas1, C R Bentley, W A Aclimandos.   

Abstract

The accommodative convergence/accommodation (AC/A) ratio is used clinically as a diagnostic tool in the assessment of convergence excess and near esotropia and the differentiation of true and simulated divergence excess. An abnormally high AC/A ratio has been implicated in the aetiology of some forms of strabismus but the evidence for alteration in the ratio following surgery is inconclusive. In a prospective study of 38 patients the effect of routine squint surgery was investigated in concomitant strabismus. The AC/A ratio was found to decrease significantly after surgery in both esotropes and exotropes. Furthermore a trend was demonstrated which suggested an increased risk of overcorrection in esotropes with a high (> or = 7:1) pre-operative AC/A ratio.

Entities:  

Mesh:

Year:  1994        PMID: 8013701     DOI: 10.1038/eye.1994.21

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  4 in total

1.  Y-splitting medial rectus muscle and recession in treatment for convergence excess esotropia.

Authors:  Li-Juan Huang; Yu-Yu Wu; Ning-Dong Li
Journal:  Int J Ophthalmol       Date:  2022-04-18       Impact factor: 1.779

2.  The analysis of AC/A ratio in nonrefractive accommodative esotropia treated with bifocal glasses.

Authors:  Wook Kyum Kim; Sung Yong Kang; Soolienah Rhiu; Seung Ah Chung; Jong Bok Lee
Journal:  Korean J Ophthalmol       Date:  2012-01-14

3.  Functional acute acquired comitant esotropia: clinical characteristics and efficacy of single Botulinum toxin type A injection.

Authors:  Luyao Tong; Xiaoning Yu; Xiajing Tang; Yidong Zhang; Sifan Zheng; Zhaohui Sun
Journal:  BMC Ophthalmol       Date:  2020-11-25       Impact factor: 2.209

4.  High Accommodative Convergence/Accommodation Ratio Consecutive Esotropia Following Surgery for Intermittent Exotropia: Clinical Feature, Diagnosis, and Treatment.

Authors:  Byung Joo Lee; Hyun Taek Lim
Journal:  J Clin Med       Date:  2021-05-15       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.